Work

Prediction of Benefit From Adjuvant Pertuzumab by 80-Gene Signature in the APHINITY (BIG 4-11) Trial

Year: 2024

Type: article

Source: JCO Precision Oncology

DOI: 10.1200/po.22.00667

Authors: Ian E. Krop, Lorenza Mittempergher, Joseph N. Paulson, Fabrice Andre, Herve Bonnefoi, Sherene Loi, Sibylle Loibl, Richard D. Gelber, Carmela Caballero, Rajith Bhaskaran, Christa Dreezen, Andrea R. Menicucci, Rene Bernards, Laura J. van ’t Veer, Martine J. Piccart

Institutions: Yale Cancer Center, Agendia (Netherlands), Genentech, Institut Gustave Roussy, Peter MacCallum Cancer Centre, Goethe University Frankfurt, Harvard University, Dana-Farber Cancer Institute, Frontier Science & Technology Research Foundation, Inc., Breast International Group

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4390967494

FWCI: 0.272

Cites: 34

Cited by: 2

Related to: 10